| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
| ln Vivo |
Terephthalic acid can be used to create mice tumor models in animal modeling.
|
|---|---|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
The concentration of terephthalic acid (TPA) in the urine of rats after a single oral dose of 100 mg/kg body weight was determined by high-performance liquid chromatography (HPLC). The results showed that TPA elimination conformed to first-order kinetics and a two-compartment model. The urinary excretion rates of TPA were approximately 50%, 52%, and 53% at 0-24 hours, 0-48 hours, and 0-72 hours after administration, respectively. TPA was well absorbed orally and rapidly excreted in the urine. The urinary TPA concentration at the end of the work period can serve as a biomarker for occupational exposure. After absorption through the gastrointestinal tract, terephthalic acid is mainly excreted unchanged in the urine. Skin or ocular absorption is negligible. The pharmacokinetics of (14)C terephthalic acid were determined in Fischer-344 rats by intravenous and oral administration. Plasma concentration-time data after intravenous injection were fitted using a three-compartment pharmacokinetic model. The mean terminal half-life in the three rats was 1.2 ± 0.4 hours, and the mean terminal volume of distribution was 1.3 ± 0.3 L/kg. The prolonged terminal half-life after gavage administration suggests that dissolution or intestinal absorption of (14)-CTA may be partly the rate-limiting step. Following intravenous bolus administration, the recovery rate of (14)-CTA in urine was 101 ± 8%, indicating that the compound was almost completely excreted in the urine. High-performance liquid chromatography analysis of urine revealed no evidence of (14)-CTA metabolism. (14)-CTA was transported to the fetus after administration of the compound to pregnant rats; the concentration in fetal tissues was lower than that in the corresponding maternal tissues. Newborn rats fed a diet containing 5% TPA before starting independent feeding did not develop stones. TPA is rapidly excreted into the urine after administration to rats, and the maternal excretion mechanism provides an effective defense mechanism against TPA-induced urinary tract stones in newborn rats. Using the Sperber in vivo chicken preparation method, radiolabeled terephthalic acid ([14C]TPA) was injected into the renal portal vein circulation, and the results showed that the unmodified compound was excreted into the urine via first-pass metabolism. This model was further used to characterize the excretion and transport of [14C]TPA and to provide information on the structure-specific secretion of dicarboxylic acids. The infusion rate was 0.4 nmol/min. 60% of the [14C]TPA reaching the kidneys was directly excreted. Infusion rates of 3 or 6 μmol/min resulted in complete renal clearance of [14C]TPA. These results indicate that at an infusion rate of 0.4 nmol/min, TPA is both actively secreted and actively reabsorbed; however, at higher TPA concentrations, active reabsorption becomes saturated. Secretion also becomes saturated at an infusion rate of 40 μmol/min. Infusions of probenecid, salicylates, and m-hydroxybenzoic acid inhibited the excretion and transport of TPA, suggesting that these organic acids share the same organic anion excretion and transport mechanism. m-Hydroxybenzoic acid did not affect the excretion and transport of para-aminohippuric acid (PAH) as measured simultaneously, suggesting that the secretion of TPA and PAH involves different systems. The structural specificity of dicarboxylic acid renal secretion was revealed by using phthalic acid and isophthalic acid as potential inhibitors of TPA secretion. Isophthalic acid (rather than phthalic acid) inhibited the excretion and transport of TPA, indicating that the renal secretion of carboxylated benzoic acid has a certain specificity. TPA can be actively accumulated in rat and human cadaveric renal cortical sections. (14)C-labeled terephthalic acid may be secreted and reabsorbed by nephrons, and its excretion efficiency is comparable to that of para-aminohippuric acid and tetraethylammonium when infused at a rate of 3 or 6 μmol/min. Metabolism/Metabolites A spp. of Rhodococcus was isolated from soil by enrichment culture using dimethyl terephthalate as the sole carbon source. This organism degrades dimethyl terephthalate via ester bond hydrolysis to generate free terephthalic acid, which is then metabolized via protocatechuic acid via ortho-cleavage. After intravenous injection of 14C terephthalic acid (TPA) into Fischer-344 rats, high-performance liquid chromatography (HPLC) analysis of urine revealed no evidence of TPA metabolism. Biological half-life…The concentration of TPA in urine after a single oral dose of 100 mg/kg body weight in rats was determined by HPLC. …The results indicate that TPA elimination follows first-order kinetics and a two-compartment model. The main toxicokinetic parameters are as follows: Ka = 0.51/hr, half-life ka = 0.488 hr, half-life α = 2.446 hr, time to peak concentration = 2.160 hr, Ku = 0.143/hr, half-life β = 31.551 hr, Xu(max) = 10.00 mg. …… The pharmacokinetics of 14C-labeled terephthalic acid were determined in Fischer 344 rats by intravenous injection and oral administration. After intravenous injection, plasma concentration-time data were fitted using a three-compartment pharmacokinetic model. The mean terminal half-life in rats was 1.2 hours, and the mean volume of distribution of the terminal phase was 1.3 L/kg. (14)C-terephthalic acid has a short elimination half-life in plasma (approximately 60-100 minutes); however, the apparent half-life is longer after gavage administration. |
| Toxicity/Toxicokinetics |
Interactions
The efficacy of certain antibiotics (such as tetracycline) is enhanced. Chlorosulfuric acid or dietary bicarbonate can eliminate terephthalic acid urinary calculi induced in weaned male Fisher 344 rats (days 28-42 after birth) after 2 weeks of feeding a diet containing 4.0% terephthalic acid. 14C-labeled terephthalic acid can be secreted and reabsorbed by nephrons, and its excretion efficiency is comparable to that of para-aminohippuric acid and tetraethylammonium when infused at a rate of 3 or 6 μmol/min. Probenecid significantly inhibits the excretion of 14C-labeled terephthalic acid. m-Hydroxybenzoic acid significantly reduces the excretion of 14C-labeled terephthalic acid, but has no significant effect on the excretion of para-aminohippuric acid. This study investigated the damaging effects and mechanisms of the combined action of terephthalic acid (TPA), ethylene glycol (EG), and/or dowsonic acid A (DOW): [SRP: a mixture of biphenyl and biphenyl oxides] on rat liver. A 2(3) factorial design was used for subchronic toxicity testing. Enzymatic, biochemical, and morphological indicators reflecting liver damage were detected. The results showed that the serum alanine aminotransferase (ALT) and total bile acid (TBA) levels in the combined poisoning group were significantly higher than those in the single poisoning group and the control group. Factor analysis showed that the combined effects of TPA, EG, and/or DOW could be classified into additive effects (TPA + EG), synergistic effects (EG + DOW), synergistic effects (TPA + DOW), and additive effects (TPA + EG + DOW). This inference was determined through morphological observation. This study investigated liver and kidney damage in workers exposed to terephthalic acid (TPA), ethylene glycol (EG), and/or Dow A (DOW), and studied early biomonitoring indicators. An occupational epidemiological survey was conducted at a chemical fiber company, and changes in liver and kidney function in workers exposed to TPA, EG, and DOW were analyzed. In the TPA+EG+DOW group, male serum gamma-glutamyl transferase (GGT) and total bile acid (TBA) levels were (35.45±16.09) U/L and (10.29±6.76) μmol/L, respectively. In the TPA+EG+DOW group, female serum alanine aminotransferase (ALT) and TBA levels were (30.68±8.58) U/L and (9.53±6.63) μmol/L, respectively. Both were significantly higher than those in the TPA group, DOW group, and control group (P<0.05, P<0.01). Compared with the TPA group, DOW group, and control group, the urinary N-acetyl-β-D-glucosidase (NAG) and β2-microglobulin (β2-MG) levels were significantly elevated in both men and women in the TPA+EG+DOW group (P < 0.05, P < 0.01), at (5.68 ± 4.01) U/mmol Cr and (23.49 ± 13.44) mg/mol Cr, and (6.68 ± 4.68) U/mmol Cr and (22.80 ± 13.00) mg/mol Cr, respectively. Regression analysis showed that after adjusting for confounding factors such as sex, smoking, and alcohol consumption, liver and kidney injury in workers was significantly associated with exposure to TPA, EG, and DOW (P < 0.001). Based on current knowledge, it is reasonable to infer that combined action should be taken to address liver and kidney injury in workers caused by terephthalic acid (TPA), ethylene glycol (EG), and/or Dow (DOW). Serum alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), thiobarbituric acid (TBA), urinary N-acetylcysteine (NAG), and β2-microglobulin (β2-MG) are recommended as biomarkers for liver and kidney injury. Non-human toxicity values Mouse intravenous LD50: 770 mg/kg Mouse intraperitoneal LD50: 1900 mg/kg Mouse intraperitoneal LD50: 880 mg/kg Rat intraperitoneal LD50: 1210 mg/kg For more non-human toxicity values (complete data) for terephthalic acid (17 items in total), please visit the HSDB record page. |
| References | |
| Additional Infomation |
Terephthalic acid is a white powder. (NTP, 1992)
Terephthalic acid is a phthalic acid with carboxyl groups at positions 1 and 4. It is one of the three isomers of phthalic acid, the other two being phthalic acid and isophthalic acid. It is the conjugate acid of terephthalic acid (1-). Terephthalic acid has been reported in cassia seeds, Arabidopsis thaliana, and other organisms with relevant data. See also: polyethylene terephthalate (monomer); polybutylene terephthalate (monomer)...see more... Mechanism of Action This study aimed to investigate the metabolism and mechanism of action of terephthalic acid (TPA) in rats. Metabolism was assessed by incubating sodium terephthalate (NaTPA) with normal rat liver microsomes, phenobarbital-pretreated microsomes, 3-methylcholanthrene, or a dietary control treated with an NADPH generation system. High-performance liquid chromatography (HPLC) was used to determine the mutagenicity of Salmonella Typhimurium strain NM2009. CYP4B1 mRNA expression was detected by RT-PCR. NaTPA levels (12.5–200 μL/L) detected by HPLC were not decreased in microsomes induced by the NADPH generation system. In the NM2009 mutagenicity response system, incubation of TPA (0.025–0.1 mmol/L) with induced or uninduced liver microsomes showed no mutagenic activity. TPA exposure increased CYP4B1 mRNA expression in rat liver, kidney, and bladder. The lack of TPA metabolism in the liver and the absence of genotoxicity data observed in the NM2009 study are consistent with other previous short-term studies… |
| Molecular Formula |
C8H6O4
|
|---|---|
| Molecular Weight |
166.1308
|
| Exact Mass |
166.027
|
| CAS # |
100-21-0
|
| Related CAS # |
26876-05-1
|
| PubChem CID |
7489
|
| Appearance |
White to off-white solid powder
|
| Density |
1,51 g/cm3
|
| Boiling Point |
392.4ºC at 760 mmHg
|
| Melting Point |
300 °C
|
| Flash Point |
260°C
|
| Vapour Pressure |
1.83E-15mmHg at 25°C
|
| Index of Refraction |
1.648
|
| LogP |
1.083
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
169
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KKEYFWRCBNTPAC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H6O4/c9-7(10)5-1-2-6(4-3-5)8(11)12/h1-4H,(H,9,10)(H,11,12)
|
| Chemical Name |
terephthalic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~120.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (12.04 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (12.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0194 mL | 30.0969 mL | 60.1938 mL | |
| 5 mM | 1.2039 mL | 6.0194 mL | 12.0388 mL | |
| 10 mM | 0.6019 mL | 3.0097 mL | 6.0194 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.